Piper Jaffray analyst Christopher Raymond reported that the American Academy of Neurology posted emerging science abstract titles this morning, adding that full abstracts are not anticipated until May 3. It appears Phase 3 data on Alexion’s (ALXN) Soliris for Neuromyelitis Optica Spectrum Disorder, or NMOSD, will be presented as an emerging science abstract and that data from a Phase 1/2 study of Biogen’s (BIIB) BIIB067 in SOD1 mutant ALS patients will also be presented, making the meeting potentially “meaningful” for both. Raymond keeps Overweight ratings on Alexion and Biogen.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.